HOME >> BIOLOGY >> NEWS
Don't care for broccoli? A receptor gene's variation suggests an evolutionary excuse

By testing the bitterness perceived by individuals possessing different versions of the same taste receptor, researchers have obtained new evidence supporting the idea that evolution of the receptor gene has shaped avoidance of certain vegetables that can inhibit thyroid function. The findings are reported by Mari Hakala and Paul Breslin of Monell Chemical Sciences Center in Philadelphia, Pennsylvania and appear in the September 19th issue of Current Biology, published by Cell Press.

Compounds known as glucosinolates are present in a variety of vegetables included in the human diet (especially Cruciferous vegetables), but these compounds can block the formation of organic iodine and the transport of iodine into the thyroid. Iodine is necessary for proper thyroid function, and in geographic regions where inorganic iodine levels are low, endemic goiter (enlarged thyroid) can arise in response to the need to maintain levels of thyroid hormone. In such circumstances, thyroid toxins such as glucosinolates can exacerbate problems with thyroid function. Deficiencies in thyroid function can result in retarded sexual maturation and mental retardation in low-iodine regions (typically, remote areas far from the sea).

Past work has suggested that evolution of the TAS2R family of bitter taste receptors has been shaped by the potential advantage of avoiding certain toxic compounds in plants, but the evidence thus far has been based on findings that used synthetic bitter compounds. For example, past work showed that people possessing genetically different versions of a particular TAS2R receptor exhibit correspondingly different sensitivities to the bitter compounds phenylthiocarbamide (PTC) and propylthiouracil (PROP), which resemble glucosinolates.

In the new work, researchers were able to show that different genetic versions of this same receptor, known as hTAS2R38, specifically determine people's perception of plants that synthesize glucosinolates
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
18-Sep-2006


Page: 1 2

Related biology news :

1. Dont overlook urban soil
2. Dont move a muscle: Evolutionary insight into myogenesis
3. Dont hold your breath: Carp can manage without oxygen for months
4. Genes in Uniform: Dont Test, Dont Tell
5. Dont count on vitamin C to boost your exercise performance
6. Dont stand so close to me: A new view on how species coexist
7. Cell receptor may lead to new biomarker for pancreatic cancer
8. Menthol receptor also important in detecting cold temperatures
9. Systems characterization of cell surface receptors
10. OHSU lab finds meth receptor that could lead to therapy
11. Joslin study indicates insulin receptors play a critical role in promoting islet growth

Post Your Comments:
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/17/2014)... 17, 2014   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, announced today its presentation at ... San Francisco, CA. ... Officer, will present on Monday, January 12, 2015, at ... be webcast live and may be accessed from the ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: